Centre for Haemato-Oncology

Led by Professor John Gribben

This Centre seeks to understand the molecular basis for lymphoma, leukaemia and myeloma to identify targets for novel targeted therapies and to identify biomarkers of prognosis and response to treatment. We also seek to understand the impact of the tumour microenvironment on malignant cell survival and resistance to therapy. A long-standing strength has been the translational components with strong links to the clinic through clinical senior lecturers and clinical research fellowships and high enrolment of patients in clinical trials.  Our main research interests are:

• Cancer Immunotherapy:
  The aim is to develop immunotherapy approaches for the treatment of cancer, including stem cell transplantation; and to identify tumour antigens.

• Applied Haemato-Oncology Group:
  The aim is to characterise the molecular signature of lymphomas to identify recurrent genomic and expression changes within these lymphomas to guide treatment selection.

• Cancer Genomics:
  The aim is to understand the key genetic events in malignant transformation through molecular cytogenetics, SNP genotyping approaches and high throughput genomic sequencing.

• Clinical Cancer Pharmacology:
  We conduct pharmacodynamic and pharmacokinetic studies of cytotoxic agents to develop and test new agents in the laboratory and in clinical trials. The goal is to optimise the use of chemotherapy drugs through a better understanding of their molecular and clinical pharmacology.

Please click here for profiles of staff in the Centre for Haemato-Oncology